tiprankstipranks
Arvinas enters exclusive strategic license agreement with Novartis for ARV-766
PremiumThe FlyArvinas enters exclusive strategic license agreement with Novartis for ARV-766
9d ago
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
PremiumPress Releases
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
9d ago
Arvinas Appoints New Chief Medical Officer for Clinical Programs
PremiumCompany Announcements
Arvinas Appoints New Chief Medical Officer for Clinical Programs
1M ago
Arvinas price target raised to $59 from $33 at Wedbush
PremiumThe FlyArvinas price target raised to $59 from $33 at Wedbush
2M ago
Arvinas VERITAC-2 trial timelines not changed, says Oppenheimer
PremiumThe Fly
Arvinas VERITAC-2 trial timelines not changed, says Oppenheimer
2M ago
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2M ago
Arvinas announces resignation of CFO Sean Cassidy
PremiumThe FlyArvinas announces resignation of CFO Sean Cassidy
2M ago
Arvinas Announces Chief Financial Officer Transition
PremiumPress Releases
Arvinas Announces Chief Financial Officer Transition
2M ago
Arvinas announces first-in-human dosing of ARV-102
PremiumThe Fly
Arvinas announces first-in-human dosing of ARV-102
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100